| Bioactivity | GSK_WRN4 is a WRN helicase inhibitor (pIC50=7.6) with anticancer activity. GSK_WRN4 selectively inhibits the growth of MSI tumor cells in vitro and in vivo by inducing DNA double-strand breaks, particularly at expanded TA repeats and DNA damage regions[1]. |
| CAS | 2923008-66-4 |
| Formula | C16H20N2O4S |
| Molar Mass | 336.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Picco, et al. "Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells." Cancer Discovery 14.8 (2024): 1457-1475. |
GSK_WRN4
CAS: 2923008-66-4 F: C16H20N2O4S W: 336.41
GSK_WRN4 is a WRN helicase inhibitor (pIC50=7.6) with anticancer activity. GSK_WRN4 selectively inhibits the growth of M
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.